The Lancet Haematology/X
Jun 13, 2025, 23:21
Paul J Bröckelmann Shares The Lancet Haematology Commission Update on Adverse Events at EHA 2025
The Lancet Haematology shared a post on X:
“Today at EHA2025 Dr Paul J Bröckelmann shared insights from The Lancet Haematology Commission on Adverse Events.
Our 2025 Series updates priority areas on measuring and managing toxicities in new haematology treatment.”
Paul J Bröckelmann presented updates from The Lancet Haematology Commission’s 2025 Series at EHA 2025, focusing on improving how adverse events are measured and managed in modern haematology therapies.
You Can Find More Posts on Hemostasis Today.
-
Mar 1, 2026, 13:17Michael Makris։ Extraterrestrial Regolith as a Trigger of the Intrinsic Coagulation Pathway
-
Mar 1, 2026, 13:11Strategic Planning Day to Shape The Future of Thrombosis and Haemostasis – THANZ
-
Mar 1, 2026, 13:06Simon Senanu: Not Every Thrombocytopenia Is Real
-
Mar 1, 2026, 12:53Kevin Tang: Evolving Burden of CVD Across Asia and Its Broader Implications for Global Health Policy
-
Mar 1, 2026, 12:02Hassan Raza: Building Sustainable Support for People with Bleeding Disorders in Pakistan
-
Mar 1, 2026, 11:40Naradja Wissmar: Raised IL-32 as a Hint to Long-Term Immune Activation Post-COVID
-
Mar 1, 2026, 11:10Mehran Ghasemzadeh: A Novel Panel Bridging Platelet Function and Clinical Presentation in Chronic ITP
-
Mar 1, 2026, 10:47Tagreed Alkaltham: In Transfusion Medicine, Every Reaction Deserves An Answer
-
Mar 1, 2026, 10:31Deborah Siegal Explores ARTESiA in The CLOT Conversation’s Latest Episode